Alphatec Holdings faces a securities investigation after missing Q3 2026 earnings targets and cutting full-year guidance, triggering a 39.67% share price decline.
Alphatec reported Q3 2026 adjusted EPS of $0.09 versus a $0.10-$0.11 consensus and revenue of $221.2 million, $4.0 million below the $225.2 million estimate, while slashing full-year revenue and free cash flow guidance. Shares already fell about 39.67% on October 30, 2026, and the newly disclosed Levi & Korsinsky securities-law investigation extends the downside overhang and litigation risk for holders.
Levi & Korsinsky is probing whether Alphatec made materially false or misleading statements about its business performance before reporting Q3 2026 adjusted EPS of $0.09 and revenue of $221.2 million, both below Wall Street consensus, which sent the stock down sharply.
Yes. According to the announcement, eligibility is based on when you purchased the shares, not whether you still hold them, and submitting information for a review costs nothing upfront.
Alphatec Holdings (ATEC) is under investigation by Levi & Korsinsky following a disappointing Q3 2026 earnings report. The company missed consensus estimates for both adjusted EPS and revenue, while simultaneously slashing its full-year financial guidance. Shares plummeted nearly 40% on October 30, 2026, as management cited lower biologics attachment as the primary driver for the shortfall.
Levi & Korsinsky is probing whether Alphatec made materially false or misleading statements about its business performance before reporting Q3 2026 adjusted EPS and revenue figures that fell below Wall Street consensus.
Yes. Eligibility is based on when you purchased the shares, not whether you still hold them, and submitting information for a review costs nothing upfront.